大剂量爱维治改善糖尿病患者周围神经传导速度的研究被引量：7

Clinical study on peripheral nerve conduct velocity in patients with diabetic peripheral neuropathy treated with large dose Actovegin

下载PDF

导出

摘要目的:探讨大剂量爱维治(Actovegin)对糖尿病周围神经病变(DPN)的疗效及安全性。方法:60例DPN患者随机分为三组,大剂量组给予爱维治2 000mg,常规剂量组给予爱维治800 mg,均溶于500 m l等渗盐水中静脉滴注;对照组给予前列地尔10μg溶于100m l等渗盐水中静脉滴注,均为1次/d,共15 d,观察治疗前后主要症状和神经电生理的变化。结果:大剂量爱维治组主要症状改善明显优于常规剂量组和对照组,周围神经传导速度提高较常规剂量组和对照组也有显著性差异(P<0.05),未见不良反应。结论:大剂量爱维治比常规剂量更能改善DPN临床症状及周围神经传导速度,安全性较好。 Objective： To study the efficacy and safety of large dose Actovegin in patients with diabetic peripheral neuropathy（DPN）. Methods：Sixty patients of DPN were divided into three groups randomly ： Large dose group （ Actovegin 2 000 mg/day） , Routine dose group （ Actovegin 800 mg/day）. Control group, Lipo PGE1 10μg/day. Symptoms and nerve conduct velocity were observed. Results： The rate of symptoms improvement and nerve conduct velocity improvement are higher in large dose group than those in other two groups. Conclusion： Large dose Actovegin can improve peripheral nerve conduct velocity significantly and is safe for use.

作者顾萍赵明王燕燕王晓陆邦超卢斌李洁

机构地区第二军医大学临床医学院(南京军区南京总医院)内分泌科

出处《医学研究生学报》 CAS 2006年第9期814-816,共3页 Journal of Medical Postgraduates

关键词糖尿病周围神经传导速度爱维治 Diabetes Peripheral nerve Conduct victory Actovegin

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献7

1Sima AA,Zhang W,Grunberger G.Type 1 diabetes neuropathy and C-peptide[J].Exp Diabesity Res,2004,5(1):65-77.
2van de Poll F,Valk GD,Renders CM,et al.Longitudinal assessment of the development of diabetic polyneuropathy and associated risk factors[J].Diabet Med,2002,19(9):771-776.
3Tan W,Rouen S,Barkus KM,et al.Nerve growth factor blocks the glucose-induced down-regulation of caveolin-1 expression in Schwann cells via p75 neurotrophin receptor signaling[J].J Biol Chen,2003,278(25):23151-2362.
4Chandra D,Jackson EB,Ramana KV,et al.Nitricoxide prevents aldose reductase activation and sorbitol accumulation during diabetes[J].Diabetes,2002,51(10):3095-3101.
5Leslie RD.United kingdom prospective diabetes study.What now or so what?[J] Diabetes Metab Res Rev,1999,15(1):65-71.
6薛松,高建平,卫中庆,程文,张征宇,戴玉田,孙则禹.糖尿病兔膀胱功能障碍的实验研究[J].医学研究生学报,2003,16(7):496-498. 被引量：2
7Boiarinov GA,Penkovich AA,Mukhina IV.The metabolic effects of neurotropic action of actovegin during hypoxia[J].Eksp Klin Farmakol,1999,62(2):61-63.

二级参考文献10

1Olapade-Olaopa EO,Morley RN.Diabetic cystopathy presenting as primary acute urinary retention in a previously undiagnosed young male diabetic patient[J]. J Diabetes Complications,1997, 11(6) :350-351.
2Gupta S,Yang S,Coben RA.Altered contractility of urinary bladder in diabetic rabbits:relationship to reduced Na+ pump activity[J].Am J Physiol, 1996,271(6 Pt 1): C2045-C2052.
3Sato M,Shirai M.Diabetic urinary bladder and urethral dysfunction[J]. Nippon Rinsho,1997,55(suppl):876-880.
4Vaidyanathan S,Krisbnan KR,Mansour P et al.P75 nerve growth factor in the vesical urothelium of patients with neuropathic bladder:arimmunohistochemical study[J].Spinal Cord,1998,36(8): 541-547.
5Tong YC,Chin WT,Cheng JT et al.Alternations in urinary bladder M2-muscarinic recepter protein and mRNA in 2-week streptozotocin-induced diabetic rats[J].Neurosci Lett ,1999 ,273(3):173-176.
6Mumtaz FH,Shukla N,Sullivan ME et al.Inhibition of diabetic bladder smooth cell proliferation by endothelin receptor antagonists[J].Urol Res,2000, 28(4): 254-259.
7Kaplan SA,Blaivas JG.Diabetic cystopathy[J].J Diabetes Complications,1988,2(3):133-139.
8Watanabe T,Miyagawa I.Characteristics of detrusor contractility during micturition indiabetics[J].Neurourol Urodyn, 1999, 18(3):163-171.
9Belis JA,Curley RM,Lang CM et al.Bladder dysfunction in the spontaneously diabetic male Abyssinian-Hartley guinea pig. Pharmacology,1996, 53(1):66-70.
10唐朝克,尹卫东,徐刚,梁丽红,杨保堂,文格波.糖尿病新西兰兔模型的建立及并发糖尿病肾病的机理研究[J].南华大学学报（医学版）,2001,29(5):439-442. 被引量：8